Cardiol Therapeutics

Cardiol Therapeutics earns a Neutral rating, with a 43.3 composite score and low conviction at 2/5. The regulatory pillar leads at 66, supported by Canada’s favorable jurisdiction posture, three events across the past 180 days and no enforcement hits. Fundamentals contribute a midrange 53, reflecting stronger operating-margin scoring against weaker market-cap and cash-runway components. Editorial contributes 30, with no recent newsroom or brief activity to lift visibility. Market performance is the principal drag at 15, entirely reflecting the minimum liquidity score and reported trading volume of zero. The resulting profile supports neither a premium stance nor an outright negative call: regulatory positioning provides credible support, while thin liquidity, limited coverage and stretched finances cap the rating within the Neutral band.

Underlying fundamentals remain mixed. Year-over-year revenue growth was flat, while the reported operating margin was at break-even and earned the strongest fundamental subscore. That margin signal does not offset a net loss of roughly $31.1 million, an EBITDA loss near $35.6 million or a cash-burn ratio around 0.31. The 36.4 cash-runway subscore confirms that the financial condition remains stretched, leaving funding capacity as a material constraint. Filing activity has been consistent but not accelerated: two regulatory events occurred during the latest 90-day period and three across 180 days, producing a cadence subscore below the jurisdiction and enforcement components. The latest primary regulatory filing arrived in early July 2026. These observations are grounded in primary regulatory filings, institutional pricing feeds, licensed fundamentals data and CIN newsroom coverage.

The clearest forward catalyst sits within the regulatory pillar, where an 80 jurisdiction score and an 80 enforcement score establish the company’s strongest analytical base. Additional primary regulatory filings can raise the weaker cadence component, sharpen visibility around development progress and provide a concrete counterweight to absent editorial momentum. Sustained filing activity also enables the regulatory pillar to remain the core support for the Neutral rating while fundamentals and market liquidity lag. The single most important signal to watch is the next substantive primary regulatory filing and whether it extends the recent event cadence.